US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
*
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US20080131962A1
(en)
*
|
2006-05-25 |
2008-06-05 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
CA2667414C
(en)
|
2006-11-13 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the human glucocorticoid receptor locus
|
WO2008133938A2
(en)
|
2007-04-26 |
2008-11-06 |
Sangamo Biosciences, Inc. |
Targeted integration into the ppp1r12c locus
|
JP5666903B2
(ja)
|
2007-05-23 |
2015-02-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
導入遺伝子の発現を増強するための方法および組成物
|
CA2692453C
(en)
|
2007-07-12 |
2018-01-09 |
Trevor Collingwood |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression
|
US20110014616A1
(en)
*
|
2009-06-30 |
2011-01-20 |
Sangamo Biosciences, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
CA2700231C
(en)
*
|
2007-09-27 |
2018-09-18 |
Sangamo Biosciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
EP2205752B1
(de)
*
|
2007-10-25 |
2016-08-10 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen für gezielte integration
|
EP2297318B1
(de)
|
2008-05-28 |
2018-05-23 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zum verknüpfen von dna-bindungsdomänen und spaltungsdomänen
|
EP2294191B1
(de)
|
2008-06-10 |
2016-09-28 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur erzeugung von bax- und bak-mangel-zelllinien
|
AU2016216543B2
(en)
*
|
2008-08-22 |
2017-11-16 |
Sangamo Therapeutics, Inc. |
Methods And Compositions For Targeted Single-Stranded Cleavage And Targeted Integration
|
CN102159722B
(zh)
|
2008-08-22 |
2014-09-03 |
桑格摩生物科学股份有限公司 |
用于靶向单链切割和靶向整合的方法和组合物
|
US9458472B2
(en)
*
|
2008-10-15 |
2016-10-04 |
Massachusetts Institute Of Technology |
Detection and destruction of cancer cells using programmed genetic vectors
|
KR101673566B1
(ko)
|
2008-10-29 |
2016-11-07 |
상가모 바이오사이언스 인코포레이티드 |
글루타민 신테타제 유전자 발현을 불활성화시키기 위한 방법 및 조성물
|
US20110023154A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Silkworm genome editing with zinc finger nucleases
|
US20110023158A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Bovine genome editing with zinc finger nucleases
|
US20110030072A1
(en)
*
|
2008-12-04 |
2011-02-03 |
Sigma-Aldrich Co. |
Genome editing of immunodeficiency genes in animals
|
US20110023153A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in alzheimer's disease
|
US20110023148A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of addiction-related genes in animals
|
US20110023147A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of prion disorder-related genes in animals
|
US20110023146A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in secretase-associated disorders
|
US20110023151A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of abc transporters
|
US20110023150A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of genes associated with schizophrenia in animals
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
US20110016539A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of neurotransmission-related genes in animals
|
US20110023145A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in autism spectrum disorders
|
US20110023140A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Rabbit genome editing with zinc finger nucleases
|
US20110016540A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
|
US20110023159A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Ovine genome editing with zinc finger nucleases
|
US20110023143A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of neurodevelopmental genes in animals
|
US20110016541A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genome editing of sensory-related genes in animals
|
US20110023156A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Feline genome editing with zinc finger nucleases
|
US20110023149A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in tumor suppression in animals
|
US20110016546A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Porcine genome editing with zinc finger nucleases
|
US20110016542A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Canine genome editing with zinc finger nucleases
|
US20110023144A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
|
US20110023139A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in cardiovascular disease
|
US20110023141A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genomic editing of genes involved with parkinson's disease
|
US20110023157A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Equine genome editing with zinc finger nucleases
|
US20110016543A1
(en)
*
|
2008-12-04 |
2011-01-20 |
Sigma-Aldrich Co. |
Genomic editing of genes involved in inflammation
|
JP5681114B2
(ja)
|
2008-12-04 |
2015-03-04 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集
|
AU2009333863B2
(en)
|
2008-12-17 |
2015-02-05 |
Corteva Agriscience Llc |
Targeted integration into the Zp15 locus
|
CA2755192C
(en)
|
2009-03-20 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
JP6215533B2
(ja)
|
2009-04-09 |
2017-10-18 |
サンガモ セラピューティクス, インコーポレイテッド |
幹細胞への標的組込み
|
US8772008B2
(en)
*
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
EP2727600B1
(de)
|
2009-07-28 |
2019-03-27 |
Sangamo Therapeutics, Inc. |
Zinkfingerfusionsproteine zur supprimierung eines huntington gens
|
US20110041195A1
(en)
|
2009-08-11 |
2011-02-17 |
Sangamo Biosciences, Inc. |
Organisms homozygous for targeted modification
|
US8592645B2
(en)
|
2009-10-22 |
2013-11-26 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
WO2011086118A1
(en)
*
|
2010-01-14 |
2011-07-21 |
Deutsches Krebsforschungszentrum |
In vivo determination of the lokalization of dna double-stand breaks and application thereof
|
WO2011091324A2
(en)
*
|
2010-01-22 |
2011-07-28 |
The Scripps Research Institute |
Methods of generating zinc finger nucleases having altered activity
|
AU2011207769B2
(en)
|
2010-01-22 |
2015-05-28 |
Corteva Agriscience Llc |
Targeted genomic alteration
|
JP6137596B2
(ja)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス, インコーポレイテッド |
遺伝子操作された切断ハーフドメイン
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
KR101880536B1
(ko)
|
2010-04-26 |
2018-07-23 |
상가모 테라퓨틱스, 인코포레이티드 |
아연 핑거 뉴클레아제를 사용하는 로사 좌위의 게놈 편집
|
HUE048072T2
(hu)
|
2010-05-03 |
2020-05-28 |
Sangamo Therapeutics Inc |
Készítmények cinkujj-modulok összekapcsolására
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
CA2993567C
(en)
|
2010-07-21 |
2022-06-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
WO2012012738A1
(en)
|
2010-07-23 |
2012-01-26 |
Sigma-Aldrich Co., Llc |
Genome editing using targeting endonucleases and single-stranded nucleic acids
|
WO2012015938A2
(en)
*
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
KR101930711B1
(ko)
|
2010-10-12 |
2018-12-19 |
더 칠드런스 호스피탈 오브 필라델피아 |
혈우병 b의 치료를 위한 방법 및 조성물
|
JP2014513520A
(ja)
|
2010-12-29 |
2014-06-05 |
シグマ−アルドリッチ・カンパニー、エルエルシー |
Admeおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
WO2012168910A1
(en)
|
2011-06-10 |
2012-12-13 |
Basf Plant Science Company Gmbh |
Nuclease fusion protein and uses thereof
|
AU2012284365B2
(en)
|
2011-07-15 |
2017-04-20 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
JP6185916B2
(ja)
|
2011-09-21 |
2017-08-23 |
サンガモ セラピューティクス, インコーポレイテッド |
導入遺伝子発現を制御するための方法および組成物
|
EP2771457B1
(de)
|
2011-10-27 |
2017-11-22 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur veränderung des hprt-locus
|
US9458205B2
(en)
|
2011-11-16 |
2016-10-04 |
Sangamo Biosciences, Inc. |
Modified DNA-binding proteins and uses thereof
|
EP2612918A1
(de)
|
2012-01-06 |
2013-07-10 |
BASF Plant Science Company GmbH |
In planta-Rekombination
|
WO2013130824A1
(en)
|
2012-02-29 |
2013-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
CN103361328B
(zh)
*
|
2012-03-30 |
2017-08-18 |
复旦大学 |
介导整合的hiv‑1前病毒基因敲除的锌指核酸内切酶及其制法和应用
|
WO2013152220A2
(en)
|
2012-04-04 |
2013-10-10 |
Life Technologies Corporation |
Tal-effector assembly platform, customized services, kits and assays
|
CN102627690B
(zh)
*
|
2012-04-05 |
2014-12-17 |
浙江大学 |
一对转录激活子样效应因子核酸酶及其编码基因与应用
|
MX344903B
(es)
|
2012-05-02 |
2017-01-11 |
Dow Agrosciences Llc |
Modificación dirigida de deshidrogenasa de malato.
|
WO2013169802A1
(en)
|
2012-05-07 |
2013-11-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
WO2013169398A2
(en)
|
2012-05-09 |
2013-11-14 |
Georgia Tech Research Corporation |
Systems and methods for improving nuclease specificity and activity
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
AU2013289206B2
(en)
|
2012-07-11 |
2018-08-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
EP2872154B1
(de)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
|
SG11201500852WA
(en)
|
2012-08-29 |
2015-04-29 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
BR112015004995B1
(pt)
|
2012-09-07 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Método para modificação do genoma de uma célula, uso de uma célula, semente ou planta obtida pelo referido método e nuclease de dedo de zinco sítio específica
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
WO2014059255A1
(en)
|
2012-10-12 |
2014-04-17 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
JP2016500254A
(ja)
|
2012-12-05 |
2016-01-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
代謝疾患の調節のための方法および組成物
|
CA2895117A1
(en)
|
2012-12-13 |
2014-06-19 |
James W. Bing |
Precision gene targeting to a particular locus in maize
|
CN104995302B
(zh)
|
2013-01-16 |
2021-08-31 |
爱默蕾大学 |
Cas9-核酸复合物及其相关用途
|
US10676749B2
(en)
|
2013-02-07 |
2020-06-09 |
The General Hospital Corporation |
Tale transcriptional activators
|
WO2014130955A1
(en)
|
2013-02-25 |
2014-08-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
WO2014144592A2
(en)
|
2013-03-15 |
2014-09-18 |
The General Hospital Corporation |
Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
CA2906970C
(en)
|
2013-03-21 |
2021-05-18 |
Ospedale San Raffaele Srl |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
RU2723130C2
(ru)
|
2013-04-05 |
2020-06-08 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Способы и композиции для встраивания экзогенной последовательности в геном растений
|
CA2910427C
(en)
|
2013-05-10 |
2024-02-20 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2014186585A2
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
JP6588438B2
(ja)
|
2013-08-28 |
2019-10-09 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
US10117899B2
(en)
|
2013-10-17 |
2018-11-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
US9957526B2
(en)
|
2013-10-17 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
NZ719494A
(en)
|
2013-11-04 |
2017-09-29 |
Dow Agrosciences Llc |
Optimal maize loci
|
US10273493B2
(en)
|
2013-11-04 |
2019-04-30 |
Dow Agrosciences Llc |
Optimal maize loci
|
BR102014027436B1
(pt)
|
2013-11-04 |
2022-06-28 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, e método para a produção de uma célula vegetal transgênica
|
RU2016120636A
(ru)
|
2013-11-04 |
2017-12-06 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Оптимальные локусы сои
|
LT3066201T
(lt)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
|
MX2016006106A
(es)
|
2013-11-11 |
2016-12-09 |
Sangamo Biosciences Inc |
Metodos y composiciones para tratar la enfermedad de huntington.
|
RS58671B1
(sr)
|
2013-11-13 |
2019-06-28 |
Childrens Medical Center |
Regulacija genske ekspresije posredovana nukleazama
|
US10081661B2
(en)
|
2013-12-09 |
2018-09-25 |
Sangamo Therapeutics, Inc. |
Methods and compositions for genome engineering
|
RS60514B1
(sr)
|
2014-02-03 |
2020-08-31 |
Sangamo Therapeutics Inc |
Postupci i sastavi za tretman beta talasemije
|
WO2015127439A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
JP6594891B2
(ja)
|
2014-03-18 |
2019-10-23 |
サンガモ セラピューティクス, インコーポレイテッド |
ジンクフィンガータンパク質発現を調節するための方法および組成物
|
US10507232B2
(en)
|
2014-04-02 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for the treatment of latent viral infection
|
US20150301028A1
(en)
|
2014-04-22 |
2015-10-22 |
Q-State Biosciences, Inc. |
Analysis of compounds for pain and sensory disorders
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
BR112016025849A2
(pt)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
métodos e composições para o tratamento da doença de huntington
|
AU2015259191B2
(en)
|
2014-05-13 |
2019-03-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for prevention or treatment of a disease
|
AU2015266776A1
(en)
|
2014-05-30 |
2016-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
WO2015188065A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
AU2015289799B2
(en)
|
2014-07-14 |
2018-07-26 |
The University Court Of The University Of Edinburgh |
NANOS knock-out that ablates germline cells
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
LT3194570T
(lt)
|
2014-09-16 |
2021-09-27 |
Sangamo Therapeutics, Inc. |
Būdai ir kompozicijos, skirti kraujodaros kamieninių ląstelių genomo inžinerijai ir korekcijai, kuriai tarpininkauja nukleazė
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
EP3247366A4
(de)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur identifizierung hochspezifischer nukleasen
|
US10048275B2
(en)
|
2015-03-13 |
2018-08-14 |
Q-State Biosciences, Inc. |
Cardiotoxicity screening methods
|
EP4335918A3
(de)
|
2015-04-03 |
2024-04-17 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur genomeditierung von b-zellen
|
US10738290B2
(en)
|
2015-04-21 |
2020-08-11 |
Novartis Ag |
RNA-guided gene editing system and uses thereof
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
JP6873917B2
(ja)
|
2015-05-12 |
2021-05-19 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ介在性遺伝子発現調節
|
EP3298448A4
(de)
|
2015-05-21 |
2019-03-27 |
Q-State Biosciences, Inc. |
Optogenetisches mikroskop
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
EP3324999A1
(de)
|
2015-05-29 |
2018-05-30 |
Agenovir Corporation |
Zusammensetzungen und verfahren für zellgerichtete hpv-behandlung
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
JP2018525000A
(ja)
|
2015-08-06 |
2018-09-06 |
ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri |
改変cd163遺伝子を有する病原体抵抗性動物
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
BR112018005779A2
(pt)
|
2015-09-23 |
2018-10-09 |
Sangamo Therapeutics, Inc. |
repressores de htt e usos dos mesmos
|
AU2016343887B2
(en)
|
2015-10-28 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
WO2017091512A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Biosciences, Inc. |
Methods and compositions for engineering immunity
|
CA3008382A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the mhc cell receptor
|
CA3008413A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
BR112018014288A2
(pt)
|
2016-01-15 |
2018-12-18 |
Univ Minnesota |
métodos e composições para o tratamento de doença neurológica
|
JP7012650B2
(ja)
|
2016-02-02 |
2022-01-28 |
サンガモ セラピューティクス, インコーポレイテッド |
Dna結合ドメインと切断ドメインとを連結するための組成物
|
WO2017165655A1
(en)
|
2016-03-23 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
WO2018013840A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
JP7134944B2
(ja)
|
2016-08-11 |
2022-09-12 |
ザ ジャクソン ラボラトリー |
遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
|
JP7272948B2
(ja)
|
2016-08-24 |
2023-05-12 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的ヌクレアーゼ
|
BR112019003100A2
(pt)
|
2016-08-24 |
2019-07-09 |
Sangamo Therapeutics Inc |
regulação da expressão gênica usando nucleases manipuladas
|
JP7256739B2
(ja)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス, インコーポレイテッド |
肝臓遺伝子のモジュレーション
|
CN110022904B
(zh)
|
2016-10-20 |
2024-04-19 |
桑格摩生物治疗股份有限公司 |
用于治疗法布里病的方法和组合物
|
CA3041668A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
IL266862B2
(en)
|
2016-12-01 |
2024-01-01 |
Sangamo Therapeutics Inc |
Tau modulators and methods and preparations for their administration
|
JP7416406B2
(ja)
|
2016-12-08 |
2024-01-17 |
ケース ウェスタン リザーブ ユニバーシティ |
機能的ミエリン産生を増進させるための方法および組成物
|
EP4317447A3
(de)
|
2017-02-15 |
2024-05-01 |
2seventy bio, Inc. |
Multiplex-genomeditierung für spenderreparaturmatrizen
|
JP2020515248A
(ja)
|
2017-03-21 |
2020-05-28 |
ザ ジャクソン ラボラトリーThe Jackson Laboratory |
ヒトAPOE4およびマウスTrem2 p.R47Hを発現する遺伝子改変されたマウス、ならびにその使用の方法
|
CA3061612A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
CA3063368A1
(en)
|
2017-05-12 |
2018-11-15 |
The Jackson Laboratory |
Nsg mice lacking mhc class i and class ii
|
US11566223B2
(en)
|
2017-06-01 |
2023-01-31 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
WO2019028023A2
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID
|
BR112020001364A2
(pt)
|
2017-07-31 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
|
EP3585161A1
(de)
|
2017-07-31 |
2020-01-01 |
Regeneron Pharmaceuticals, Inc. |
In-vivo-beurteilung von crispr/cas-induzierter rekombination mit einer exogenen donornukleinsäure
|
EP3673054A4
(de)
|
2017-08-22 |
2021-06-02 |
Napigen, Inc. |
Organellengenommodifikation unter verwendung von polynukleotid-geführter endonuklease
|
BR112020008568A2
(pt)
|
2017-11-09 |
2020-10-06 |
Sangamo Therapeutics, Inc. |
modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
|
US20220265708A1
(en)
|
2018-01-11 |
2022-08-25 |
Innovative Cellular Therapeutics, Inc. |
Modified Cell Expansion and Uses Thereof
|
JP7466448B2
(ja)
|
2018-01-17 |
2024-04-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Dna-pk阻害剤
|
BR112020013626A2
(pt)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
compostos de quinoxalinona, composições, métodos e kits para aumentar a eficiência de edição de genoma
|
CN111757876B
(zh)
|
2018-01-17 |
2024-03-22 |
沃泰克斯药物股份有限公司 |
Dna-pk抑制剂
|
WO2019152941A1
(en)
|
2018-02-05 |
2019-08-08 |
Caribou Biosciences, Inc. |
Engineered gut microbes for reduction of reactivation of detoxified drugs
|
SG11202007440YA
(en)
|
2018-02-08 |
2020-09-29 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
US20220267420A1
(en)
|
2018-02-15 |
2022-08-25 |
Memorial Sloan Kettering Cancer Center |
Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
|
KR102647714B1
(ko)
|
2018-03-19 |
2024-03-18 |
리제너론 파마슈티칼스 인코포레이티드 |
CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
US20210015869A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
JP6614622B2
(ja)
*
|
2018-04-17 |
2019-12-04 |
国立大学法人名古屋大学 |
植物ゲノム編集方法
|
JP7332622B2
(ja)
|
2018-04-18 |
2023-08-23 |
サンガモ セラピューティクス, インコーポレイテッド |
ハンチンチン(htt)の調節のためのジンクフィンガータンパク質組成物
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
KR20210049124A
(ko)
|
2018-08-23 |
2021-05-04 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
KR20210060533A
(ko)
|
2018-09-18 |
2021-05-26 |
상가모 테라퓨틱스, 인코포레이티드 |
프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
|
EP3886869A4
(de)
|
2018-11-28 |
2022-07-06 |
Forty Seven, Inc. |
Genetisch modifizierte ablationsresistente hspcs
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
WO2020150338A1
(en)
*
|
2019-01-15 |
2020-07-23 |
Sangamo Therapeutics, Inc. |
Htt repressors and uses thereof
|
US20220162583A1
(en)
*
|
2019-01-28 |
2022-05-26 |
Mayo Foundation For Medical Education And Research |
Mitochondrial genome editing methods
|
US11857641B2
(en)
|
2019-02-06 |
2024-01-02 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type I
|
US20220290120A1
(en)
|
2019-02-25 |
2022-09-15 |
Novome Biotechnologies, Inc. |
Plasmids for gene editing
|
CN115141807A
(zh)
|
2019-04-02 |
2022-10-04 |
桑格摩生物治疗股份有限公司 |
治疗β-地中海贫血症的方法
|
CA3133361A1
(en)
|
2019-04-03 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
WO2020223535A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
US20200368279A1
(en)
|
2019-05-21 |
2020-11-26 |
Sangamo Therapeutics, Inc. |
Controlled Transgene Expression in Regulatory T Cells
|
WO2021003410A1
(en)
*
|
2019-07-03 |
2021-01-07 |
Napigen, Inc. |
Organelle genome modification
|
US20230079440A1
(en)
|
2019-11-01 |
2023-03-16 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
CN114746125A
(zh)
|
2019-11-08 |
2022-07-12 |
瑞泽恩制药公司 |
用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
CN115715203A
(zh)
|
2020-05-06 |
2023-02-24 |
塞勒克提斯公司 |
对细胞进行基因修饰以递送治疗性蛋白质的方法
|
US20230181641A1
(en)
|
2020-05-13 |
2023-06-15 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
EP4182297A1
(de)
|
2020-07-16 |
2023-05-24 |
Acuitas Therapeutics, Inc. |
Kationische lipide zur verwendung in lipidnanopartikeln
|
EP4204545A2
(de)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
EP4240756A1
(de)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Zellen zur expression eines chimären rezeptors aus einem modifizierten invarianten kettenlocus der cd3-immunglobulin-superfamilie und zugehörige polynukleotide und verfahren
|
WO2022101641A1
(en)
|
2020-11-16 |
2022-05-19 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
JP7125727B1
(ja)
|
2021-09-07 |
2022-08-25 |
国立大学法人千葉大学 |
核酸配列改変用組成物および核酸配列の標的部位を改変する方法
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
AU2022379633A1
(en)
|
2021-10-27 |
2024-04-11 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for expressing factor ix for hemophilia b therapy
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
WO2023150620A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Crispr-mediated transgene insertion in neonatal cells
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|